Addressing the inaugural session of India Global Week 2020, a three-day virtual conference organized in the United Kingdom, Prime Minister Narendra Modi said that the ongoing novel coronavirus pandemic has proved that Indian pharma is an asset for the entire world.
“The pandemic has once again shown that India’s pharma industry is an asset not just for India but for the entire world. It has played a leading role in reducing the cost of medicines especially for developing countries,” PM Modi said.
Describing India as a power-house of talent eager to contribute, PM Modi said that the country will play a key role in the development of a vaccine to combat COVID-19 as well in the global revival post the end of the crisis.
“Vaccines made in India are responsible for two-thirds of the vaccination needs of children all over the world. Even today our companies are active in international efforts for the development and production of the COVID-19 vaccine. I am certain that India will have an important role in developing and in scaling-up production of the vaccine, once it is discovered,” the Prime Minister added.
India’s COVID-19 vaccine candidate updates
Recently, India’s first indigenous novel coronavirus vaccine candidate, COVAXIN, received the nod from Drug Controller General of India (DCGI) for phase 1 and 2 trials.
Developed by Bharat Biotech in partnership with Indian Council Medical Research (ICMR) – National Institute of Virology (NIV), COVAXIN will be tested on 375 people in phase 1 trial and on 750 people in the subsequent phase.
Sharing details of the process, NIMS director Dr K Manohar said, “We will select healthy individuals and draw blood and send the blood samples to designated labs in New Delhi. They will give the green signal. Then the medicine people will examine and the first shot of the vaccine will be given due observation.”